Best Practice & Research Clinical Haematology
Volume 20, Issue 3 , Pages 425-437 , September 2007

The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia

  • George A. Calin, MD PhD (Assistant Professor)
    • ,
  • Yuri Pekarsky, PhD (Research Assistant Professor)
    • ,
  • Carlo M. Croce, MD (The John W. Wolfe Chair in Human Cancer Genetics Professor and Chairman)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 614 292 4930.

References 

  1. Ambros V. The functions of animal microRNAs. Nature. 2004;431:350–355
  2. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–297
  3. Cullen BR. Transcription and processing of human microRNA precursors. Molecular Cell. 2004;16:861–865
  4. Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell. 2003;113:673–676
  5. Lim LP, Glasner ME, Yekta S, et al. Vertebrate microRNA genes. Science. 2003;299:1540
  6. Berezikov E, Guryev V, van de Belt J, et al. Phylogenetic shadowing and computational identification of human microRNA genes. Cell. 2005;120:21–24
  7. Xie X, Lu J, Kulbokas EJ, et al. Systematic discovery of regulatory motifs in human promoters and 3′ UTRs by comparison of several mammals. Nature. 2005;434:338–345
  8. Harfe BD. MicroRNAs in vertebrate development. Current Opinion in Genetics & Development. 2005;15:410–415
  9. Calin GA, Ferracin M, Cimmino A, et al. A unique microRNA signature associated with prognostic factors and disease progression in B cell chronic lymphocytic leukemia. The New England Journal of Medicine. 2005;352:1667–1676
  10. Kluiver J, Poppema S, de Jong D, et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. The Journal of Pathology. 2005;207:243–249
  11. Eis PS, Tam W, Sun L, et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America. 2005;102:3627–3632
  12. Costinean S. Pre B cell proliferation and lymphoblastic leukemia/high grade lymphoma in Emiu miR 155 transgenic mice. Proceedings of the National Academy of Sciences of the United States of America. 2006;103:7024–7029
  13. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proceedings of the National Academy of Sciences of the United States of America. 2004;101:2999–3004
  14. Calin GA, Garzon R, Cimmino A, et al. MicroRNAs and leukemias: how strong is the connection?. Leukemia Research. 2005;30:653–655
  15. Sevignani C, Calin GA, Siracusa LD, Croce CM. Mammalian microRNAs: a small world for fine-tuning gene expression. Mammalian Genome. 2006;17:189–202
  16. Di Leva G, Calin GA, Croce CM. MicroRNAs: fundamental facts and involvement in human diseases. Birth Defects Research. Part C, Embryo Today: Reviews. 2006;78:180–189
  17. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. The New England Journal of Medicine. 2005;352:804–815
  18. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. The New England Journal of Medicine. 2004;351:893–901
  19. Orchard JA, Ibbotson RE, Davis ZA, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet. 2004;363:105–111
  20. Kipps TJ. Chronic lymphocytic leukemia and related diseases. In:  Beutler E,  Lichtman MA,  Coller BS,  Kipps TJ,  Seligson U editor. Williams hematology. New York: McGraw-Hill; 2001;p. 1163–1194
  21. Dohner H, Stilgenbaue S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. The New England Journal of Medicine. 2000;343:1910–1916
  22. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America. 2002;99:15524–15529
  23. Stilgenbauer S, Nickolenko J, Wilhelm J, et al. Expressed sequences as candidates for a novel tumor suppressor gene at band 13q14 in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Oncogene. 1998;16:1891–1897
  24. Elnenaei MO, Hamoudi RA, Swansbury J, et al. Delineation of the minimal region of loss at 13q14 in multiple myeloma. Genes Chromosomes & Cancer. 2003;36:99–106
  25. Dong JT, Boyd JC, Frierson HF. Loss of heterozygosity at 13q14 and 13q21 in high grade, high stage prostate cancer. Prostate. 2001;49:166–171
  26. Kitada S, Andersen J, Akar S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood. 1998;91:3379–3389
  27. Adachi M, Tefferi A, Greipp PR, et al. Preferential linkage of bcl-2 to immunoglobulin light chain gene in chronic lymphocytic leukemia. The Journal of Experimental Medicine. 1990;171:559–564
  28. Cory S, Adams JM. The BCL2 family: regulators of the cellular life-or-death switch. Nature Reviews. 2002;2:647–656
  29. Sanchez-Beato M, Sanchez-Aguilera A, Piris MA. Cell cycle deregulation in B-cell lymphomas. Blood. 2003;101:1220–1235
  30. Tsujimoto Y, Finger LR, Yunis J, et al. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science. 1984;226:1097–1099
  31. Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science. 1985;228:1440–1443
  32. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proceedings of the National Academy of Sciences of the United States of America. 2005;102:13944–13949
  33. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;15:4990–4997
  34. Pekarsky Y, Santanam U, Cimmino A, et al. Tcl1 expression in CLL is regulated by miR-29 and miR-181. Cancer Research. 2006;66:11590–11593
  35. Virgilio L, Narducci MG, Isobe M, et al. Identification of the TCL1 gene involved in T-cell malignancies. Proceedings of the National Academy of Sciences of the United States of America. 1994;91:12530–12534
  36. Pekarsky Y, Calin GA, Aqeilan R, Croce CM. Chronic lymphocytic leukemia: molecular genetics and animal models. Current Topics in Microbiology and Immunology. 2005;294:51–70
  37. Herling M, Patel KA, Khalili J, et al. TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Leukemia. 2006;20:280–285
  38. Narducci MG, Pescarmona E, Lazzeri C, et al. Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues. Cancer Research. 2000;60:2095–2100
  39. Said JW, Hoyer KK, French SW, et al. TCL1 oncogene expression in B cell subsets from lymphoid hyperplasia and distinct classes of B cell lymphoma. Laboratory Investigation. 2001;81:555–564
  40. Pekarsky Y, Koval A, Hallas C, et al. Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proceedings of the National Academy of Sciences of the United States of America. 2000;97:3028–3033
  41. Laine J, Kunstle G, Obata T, et al. The protooncogene TCL1 is an Akt kinase coactivator. Molecular Cell. 2000;6:395–407
  42. Chan TO, Rittenhouse SE, Tsichlis PN. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annual Review of Biochemistry. 1999;68:965–1014
  43. Pekarsky Y, Hallas C, Croce CM. The role of TCL1 in human T-cell leukemia. Oncogene. 2001;20:5638–5643
  44. Palamarchuk A, Efanov A, Maximov V, et al. Akt phosphorylates and regulates Pdcd4 tumor suppressor protein. Cancer Research. 2005;65:11282–11286
  45. Ozes ON, Mayo LD, Gustin JA, et al. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature. 1999;401:82–85
  46. Cross DA, Alessi DR, Cohen P, et al. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995;378:785–789
  47. Du K, Montminy M. CREB is a regulatory target for the protein kinase Akt/PKB. The Journal of Biological Chemistry. 1998;273:32377–32379
  48. Mok CL, Gil-Gomez G, Williams O, et al. Bad can act as a key regulator of T cell apoptosis and T cell development. The Journal of Experimental Medicine. 1999;189:575–586
  49. Palamarchuk A, Zanesi N, Aqeilan RI, et al. Tal1 transgenic expression reveals absence of B lymphocytes. Cancer Research. 2006;66:6014–6017
  50. Ahmed NN, Franke TF, Bellacosa A, et al. The proteins encoded by c-akt and v-akt differ in post-translational modification, subcellular localization and oncogenic potential. Oncogene. 1993;8:1957–1963
  51. Bichi R, Shinton SA, Martin ES, et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proceedings of the National Academy of Sciences of the United States of America. 2002;99:6955–6960
  52. Hoyer KK, French SW, Turner DE, et al. Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America. 2002;99:14392–14397
  53. Zanesi N, Aqeilan R, Drusco A, et al. Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in E{micro}-TCL1 transgenic mice. Cancer Research. 2006;66:915–920
  54. Robak T. Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukemia. Hematology (Amsterdam, Netherlands). 2004;9:387–400
  55. Yan XJ, Albesiano E, Zanesi N, et al. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America. 2006;103:11713–11718
  56. Chiorazzi N, Ferrarini M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annual Review of Immunology. 2003;21:841–894
  57. Johnson TA, Rassenti LZ, Kipps TJ. Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features. Journal of Immunology (Baltimore, Md). 1997;158:235–246
  58. Ghiotto F, Fais F, Valetto A, et al. Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. The Journal of Clinical Investigation. 2004;113:1008–1016
  59. Griffiths-Jones S, Grocock RJ, van Dongen S, et al. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Research. 2006;(Database Issue):D140–D144
  60. Calin GA, Liu CG, Sevignani C, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proceedings of the National Academy of Sciences of the United States of America. 2004;101:11755–11760
  61. Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. The New England Journal of Medicine. 2005;353:1793–1801
  62. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science. 2004;303:83–86
  63. Ramkissoon SH, Mainwaring LA, Ogasawara Y, et al. Hematopoietic-specific microRNA expression in human cells. Leukemia Research. 2006;30:643–647

PII: S1521-6926(07)00019-9

doi: 10.1016/j.beha.2007.02.003

Best Practice & Research Clinical Haematology
Volume 20, Issue 3 , Pages 425-437 , September 2007

Article Tools

* Image Usage & Resolution